et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg
et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol
L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med
et al. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery
et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg
et al. Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol
et al. Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res
et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci
et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol
J. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus
et al. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol
et al. Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus. Dis Esophagus
L. A randomized clinical study of preoperative chemotherapy for esophageal carcinoma [in Chinese]. Zhonghua zhong liu za zhi
et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol
et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol
et al. A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma [in Chinese]. Zhonghua zhong liu za zhi
et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus
et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol
et al. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Dig Dis Sci
et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg. July–August 2005;9(6):794–802.
et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. October 1, 2003;57(2):425–433.
et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. October 2009;39(10):638–643. doi:10.1093/jjco/hyp069. Epub June 23, 2009.
et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. September 1999;17(9):2915–2921.
et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. November 1, 2011;81(3):684–690. doi:10.1016/j.ijrobp.2010.06.033. Epub October 6, 2010.
et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. March 1, 2002;20(5):1167–1174.
Japan Esophageal Society, ed. Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus. Shizuoka, Japan: Kanehara; 2012.
et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. July 15, 2003;21(14):2697–2702.
et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992–1994 Patterns of Care Study. J Clin Oncol. February 2000;18(3):455–462.
et al. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. September 2008;40(9):717–721. doi:10.1055/s-2008-1077480. Epub September 4, 2008.
R. Usefulness of endoscopic salvage treatment in a patient with local failure esophageal cancer after CRT. Gan To Kagaku Ryoho. November 2011;38(12):1945–1947.
et al. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg. September 2004;188(3):261–266.
et al. Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. Ann Thorac Surg. December 2012;94(6):1862–1868. doi:10.1016/j.athoracsur.2012.07.042. Epub September 7, 2012.
Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan (1998, 1999). 3rd ed. Tokyo, Japan: Japan Esophageal Society; 2002.
et al. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus. January 1998;11(1):35–39.
et al. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res. November–December 1999;19(6C):5515–5521.
et al. Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. Dis Esophagus
et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. March 2001;233(3):300–309.
et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. January 2003;133(1):24–31.
et al. Comparison of barium swallow, CT and thallium-201 SPECT in evaluating responses of patients with esophageal squamous cell carcinoma to preoperative chemoradiotherapy. Ann Nucl Med. October 2003;17(7):583–591.
et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. March 1, 2004;22(5):900–908.
et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer. July 20, 2004;110(6):838–844.
et al. Evaluation of tumor malignancy in esophageal squamous cell carcinoma using different characteristic factors. Anticancer Res. November–December 2005;25(6B):4005–4011.
et al. Hypermethylation of hMLH1, HPP1, p14(ARF), p16(INK4A) and APC in primary adenocarcinomas of the small bowel. Int J Cancer. September 15, 2006;119(6):1298–1302.
et al. Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. Int J Oncol. June 2006;28(6):1345–1352.
et al. Videofluoroscopic evaluation in oropharyngeal swallowing after radical esophagectomy with lymphadenectomy for esophageal cancer. Anticancer Res. November–December 2007;27(6C):4249–4254.
et al. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol. September 2007;37(9):652–657.
et al. Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients. Dis Esophagus
et al. Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery. November 2008;144(5):793–802.
et al. Expression of the prolyl isomerase Pin1 is a useful indicator of sensitivity to chemoradiotherapy in advanced esophageal squamous cell carcinoma. Oncol Rep. April 2009;21(4):853–859.
et al. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci. December 2009;100(12):2354–2360.
et al. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers. November 2009;14(7):480–485.
et al. Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Tumour Biol. August 2010;31(4):333–340.
et al. Correlation of hedgehog signal activation with chemoradiotherapy sensitivity and survival in esophageal squamous cell carcinomas. Jpn J Clin Oncol. March 2011;41(3):386–393.
et al. Early prediction of treatment response by serum CRP levels in patients with advanced esophageal cancer who underwent definitive chemoradiotherapy [in Japanese]. Gan To Kagaku Ryoho. November 2010;37(12):2237–2239.
et al. Carrier woman of Duchenne muscular dystrophy mimicking inflammatory myositis. J Korean Med Sci. April 2011;26(4):587–591.
et al. Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer. Dig Surg
et al. Early evaluation of the apoptotic index ratio is useful in predicting the efficacy of chemoradiotherapy in esophageal squamous cell carcinoma. Oncol Lett. February 2012;3(2):287–292.
et al. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res. September 15, 2012;18(18):5144–5153.
L. Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma. Genet Test Mol Biomarkers. June 2013;17(6):470–474.
et al. Small proline-rich repeat protein 3 enhances the sensitivity of esophageal cancer cells in response to DNA damage-induced apoptosis. Mol Oncol. October 2013;7(5):955–967.
et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma. Dig Surg